Vogenx, Inc.

Advances PBH Development Program Following August 2026 Initial Public Offering

Strengthens Balance Sheet with $82.1 Million in Total Cash, Cash Equivalents, and Marketable Securities

Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery

Thirty-year biopharmaceutical commercial leader transitions from the Board of Directors to Chief Commercial Officer

Appointment strengthens corporate strategy, business development and commercial readiness as the Company advances mizagliflozin following its August 2026 initial public offering

Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience

Appointment broadens independent oversight as the Company scales operations following its August 2026 initial public offering

Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented